Long COVID IRIS Study Olink Proteomics Dataset (Q10356)

Plasma samples collected from Stanford University's Infection Recovery in SARS-CoV-2 (IRIS) study participants during acute SARS-CoV-2 infection, approximately 3 months post infection, and approximately 12 months post infection were analyzed using the Olink Target 96 Inflammation panel and Olink Target 96 Immune Response panel. Proteomic data were obtained from the Olink biomarker platform and presented as "NPX" (i.e. Normalized Protein eXpression) for each protein assay. The dataset features de-identified patient metadata, including participant study number (i.e. IRIS_number), sex, long COVID status (0 = recovered; 1 = Long COVID), and timepoint of the plasma sample (i.e. acute infection sample, approximately 3 months post infection, or approximately 12 months post infection). Notes: Consistent with the World Health Organization (WHO) definition, long COVID was defined in this study as the continuation or development of symptoms three months after SARS-CoV-2 infection, which were not readily attributable to other etiologies. For acute infection samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient will have fully recovered or will have long COVID at 3 months post infection. For 3 month samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient has fully recovered or has long COVID at 3 months post infection. For 12 month samples, long COVID status (0 = recovered; 1 = Long COVID) refers to whether the patient has fully recovered or has ongoing long COVID at 12 months post infection, but these patients all had long COVID at 3 months post infection.